Huang, Alan

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 796

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature

PI3K/AKT/mTOR signaling in cancerCancer Genomics and Diagnostics

Cited by 588

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 562

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 438

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 332

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 325

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 106

VRK1 is a synthetic-lethal target in VRK2-deficient glioblastoma

Shields, J. A., Meier, S. R., Bandi, M., Mulkearns-Hubert, E. E., Hajdari, N., Ferdinez, M. D., Engel, J. L., Silver, D. J., Shen, B., Zhang, W., et al. (2022) · Cancer Research

Glioma Diagnosis and TreatmentCancer Mechanisms and Therapy

Cited by 60

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife

Neuroblastoma Research and TreatmentsLung Cancer Treatments and Mutations

Cited by 45

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research

Cancer Immunotherapy and BiomarkersHistone Deacetylase Inhibitors Research

Cited by 9